BACKGROUND: The most important cause of anemia in the world is iron deficiency. Young women are more susceptible to the formation of latent iron deficiency and iron deficiency anemia in comparison with other population groups. Iron deficiency conditions can lead to a deterioration in exercise tolerance and adaptation to them, however, the effect of latent iron deficiency and iron deficiency anemia on cognitive functions, emotional status and quality of life is still a subject of discussion, which may be due to the small number of studies in which iron deficiency conditions are studied in the absence of concomitant chronic diseases. AIM: Evaluate the effect of latent iron deficiency and iron deficiency anemia on the quality of life in young women. MATERIALS AND METHODS: a cross-sectional simultaneous study was conducted in women aged 1821 years. The occurrence of iron deficiency conditions was assessed, a study of the quality of life was conducted using the SF-36 questionnaire. In the statistical processing of the results obtained, the assessment of normality within each group was carried out using Shapiro-Wilk test. For an intergroup comparison of the results obtained between two independent groups, MannWhitney test was used, and Wilcoxon test was used when comparing the results of two dependent groups. The intergroup comparison between the three groups was carried out using KruskalWallis test. When detecting deviations from the null hypothesis, a posteriori analysis was carried out using MannWhitney test with Bonferroni correction. RESULTS: 68 subjects aged 1821 took part in the study. The median age was 18 years [18; 21]. 25 (36.7%) women were diagnosed with ID, 16 (23.5%) with IDA. The level of C-reactive protein in all subjects was 5 mg/l, median 2.4 [1.2; 3.1] mg/l. During a posteriori analysis, comparable indicators of the total blood count between the groups of healthy women and those with ID were revealed. At the same time, there were no differences in ferritin levels between the ID and IDA groups. In the study of quality of life, statistically significant intergroup differences between the study groups were obtained in the scales of general health, vital activity, role functioning due to emotional state, mental health and general mental well-being. When conducting a posteriori analysis, the number of points in the questionnaire scales turned out to be comparable between groups of healthy women and those with ID. CONCLUSIONS: data on the high incidence of latent iron deficiency and iron deficiency anemia in young women have been obtained. The presence of latent iron deficiency does not independently affect the quality of life associated with health. Mild iron deficiency anemia moderately reduces the quality of life due to the emotional component.
Despite continuous attempts to improve therapy, the outcomes of acute myeloid leukemia remain almost unchanged over last decades. Drugs made with a more complete understanding of the biology of acute myeloid leukemia do not equal the hopes for better prognosis. The best results are achieved only with high-dose chemotherapy, which is only possible for a limited number of patients. High phenotypic and genotypic heterogeneity of acute myeloid leukemia defines the relevance to develop personalized approaches to therapy, including those based on determination of individual drug sensitivity of blast cells.This article presents the results of developing an ex-vivo model of acute myeloid leukemia, as well as testing of two in vitro sensitivity assessment methods: evaluation of the genotoxicity of drugs in the micronucleus test and vitality and sensitivity to chemotherapy in sorted blast cells. Prospects of individualized therapy of acute myeloid leukemia were determined based on introduction into clinical practice and continuing the research.
Treatment of COVID-19-associated pneumonia in the overwhelming majority of cases is accompanied by empirical prescription of antibiotic therapy. According to a number of studies carried out, the addition of a bacterial infection in this disease is noted less often than in other viral pneumonias, in particular, caused by the influenza virus. In addition, the occurrence of leukocytosis in response to therapy with glucocorticosteroids (GCS) is often perceived as an attachment of bacterial flora and is the reason for initiating antibiotic therapy. Therefore, an urgent task is the correct interpretation of leukocytosis in response to GCS therapy in COVID-19. The purpose of the work was to study the dynamics of changes in the number of leukocytes, neutrophils and monocytes of venous blood in patients with moderate COVID-19 with systemic use of GCS. Also we aimed to determine the differences in these indicators between the group of patients with indirect signs of bacterial infection and the group of patients receiving GCS. We analyzed the indicators of the complete blood count of 154 patients in the temporary infectious diseases hospital in the “PATRIOT” Park of the Moscow region with confirmed moderate form of COVID-19. The comparison group (1) consisted of 128 patients without clinical signs of bacterial infection and leukocytosis on admission, who were prescribed GCS therapy. The control group (2) consisted of 26 people who, upon admission, showed signs of a bacterial infection - a cough with purulent sputum in combination with neutrophilic leukocytosis. The dynamics of cells in venous blood was assessed in patients of group (1) before the start, 3 and 6 days after the start of GCS therapy. We also compared the number of leukocytes, neutrophils and monocytes between patients with developed leukocytosis from group (1) in response to GCS therapy and group (2). As a result of the study, an increase in the number of leukocytes, neutrophils and monocytes was revealed according to the data of the complete blood count test in patients of the group (1) on days 3 and 6 of GCS therapy. All patients with developed leukocytosis (103 people) had no clinical signs of bacterial infection. In patients with developed leukocytosis from group (1), an increase in the number of monocytes was revealed (0.90 (0.84; 1.02) on day 3 of GCS and 0.94 (0.87; 1.26) on day 6 of GCS) compared with group (2) (0.61 (0.50; 0.71)), p <0.001. The number of leukocytes and neutrophils did not differ between the groups. The appearance of monocytosis when taking GCS may be due to the presence of macrophage activation syndrome in the pathogenesis of COVID-19 and, therefore, increased activation of monocytes. The use of GCS in this case leads to inhibition of the migration of monocytes to the inflammation area and to the stimulation of the production of their anti-inflammatory pool (M2 cells) by the bone marrow. This fact causes an increase in the number of monocytes in the peripheral blood. Monocytosis in response to GCS therapy can be a differential diagnostic criterion between glucocorticoid-induced leukocytosis and the addition of a bacterial infection. This may be one of the factors influencing the decision to prescribe antibiotic therapy, and may also be a criterion for the effectiveness of GCS immunosuppressive therapy in COVID-19, which requires further study.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.